In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • First Interim North American Results of a Multicentre, blinded, pilot study of a Novel Peptide in promoting Lumbar Spine Fusion.

    Final Number:
    1463

    Authors:
    Peter Jarzem BSc(Eng), MD, FRCSC; Zeeshan Sardar MD.CM., M.Sc; Greg Anderson MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: Fusion failure in transforaminal lumbar interbody fusion(TLIF) procedures is a challenging problem that can lead to poor functional outcomes. B2A is a synthetic peptide that has proven efficacy in achieving fusion in animal models and may be a cheaper but safer alternative to other BMPs while avoiding iliac crest bone graft (ICBG) harvesting morbidity.

    Methods: This is a multicenter North American, prospective pilot study. Skeletally mature patients with Degenerative Disc Disease(DDD) at L2-S1 requiring single level TLIF were randomized to 3 groups: ICBG, Prefix concentration 150µg and Prefix concentration 750µg. 39 patients (13 Control, 19 Prefix 150, 7 Prefix 750, 24 Canada, 15 USA, 19 males, 20 females) were enrolled between 2009-2010. Outcome measures included Oswestry Disability Index(ODI), Visual Analog pain Scale(VAS), and fusion as assessed by CT and dynamic flexion/extension x-rays. Patients were evaluated at 6 weeks, 3, 6 and 12 months after surgery.

    Results: Blood loss during surgery was higher in ICBG (431cc) than both Prefix 150 (251cc) and Prefix 750 (314cc). Fusion at 6 months was 42%, 32%, and 71% for ICBG, low and high dose, respectively. At 12 months, fusion was 83%, 50%, and 100% for ICBG, Prefix 150 and 750 respectively. The mean ODI was 19.9 for ICBG, 31.1 for Prefix 750 and 27.8 for Prefix 150 at 12 months; differences were not statistically significant. There were no significant differences in serum chemistry between groups. No subjects developed antibodies to B2A. Complications included; 1 adjacent level infection needing reoperation (Prefix 750), 1 seroma that was drained without consequence (Prefix 150), 2 reoperations due to non-union (Prefix 150).

    Conclusions: Prefix provides a safe alternative to ICBG and avoids donor site morbidity. Prefix 750 showed superior fusion rate to autograft at 12 months. Both Prefix groups and autograft were equivalent in improving ODI at all time-points up to 12 months.

    Patient Care: A synthetic BMP can lower patient morbidity during spinal fusion with an acceptable safety profile

    Learning Objectives: By the conclusion of this session paticipants should be able to understand the advantages and disadvantages of different graft options for acheiving spine fusion.

    References: References: 1. Cunningham BW, Atkinson BL, Hu N, Kikkawa J, Jenis L, Bryant J, Zamora PO, McAfee PC. Ceramic granules enhanced with B2A peptide for lumbar interbody spine fusion: an experimental study using an instrumented model in sheep. J Neurosurg Spine. 2009 Apr;10(4):300-7. 2. Smucker JD, Bobst JA, Petersen EB, Nepola JV, Fredericks DC. B2A peptide on ceramic granules enhance posterolateral spinal fusion in rabbits compared with autograft. Spine (Phila Pa 1976). 2008 May 20;33(12):1324-9. 3. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011 Jun;11(6):471-91. 4. Nichols TA, Sagi HC, Weber TG, Guiot BH. An alternative source of autograft bone for spinal fusion: the femur: technical case report. Neurosurgery. 2008 Mar;62(3 Suppl 1):E179; discussion E179. 5. Missiuna PC, Gandhi HS, Farrokhyar F, Harnett BE, Dore EM, Roberts B. Anatomically safe and minimally invasive transcrestal technique for procurement of autogenous cancellous bone graft from the mid-iliac crest. Can J Surg. 2011 Oct;54(5):327-32 6. Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am. 2011 Dec 7;93(23):2227-36. Review. 7. Solchaga LA, Hee CK, Aguiar DJ, Ratliff J, Turner AS, Seim HB 3rd, Hollinger JO, Snel LB, Lynch SE. Augment® Bone Graft Products Compare Favorably to Autologous Bone Graft in an Ovine Model of Lumbar Interbody Spine Fusion. Spine (Phila Pa 1976). 2011 Oct 21. 8. Ilharreborde B, Morel E, Fitoussi F, Presedo A, Souchet P, Penneçot GF, Mazda K. Bioactive glass as a bone substitute for spinal fusion in adolescent idiopathic scoliosis: a comparative study with iliac crest autograft. J Pediatr Orthop. 2008 Apr-May;28(3):347-51. 9. Jeong GK, Sandhu HS, Farmer J. Bone morphogenic proteins: applications in spinal surgery. HSS J. 2005 Sep;1(1):110-7. 10. Kwon B, Jenis LG. Carrier materials for spinal fusion. Spine J. 2005 Nov-Dec;5(6 Suppl):224S-230S. Review. 11. Dimitriou R, Mataliotakis GI, Angoules AG, Kanakaris NK, Giannoudis PV. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury. 2011 Sep;42 Suppl 2:S3-15. Epub 2011 Jun 25. Review. 12. Glassman SD, Howard J, Dimar J, Sweet A, Wilson G, Carreon L. Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases. Spine (Phila Pa 1976). 2011 Oct 15;36(22):1849-54. 13. De Riu G, Meloni SM, Raho MT, Gobbi R, Tullio A. Delayed iliac abscess as an unusual complication of an iliac bone graft in an orthognathic case. Int J Oral Maxillofac Surg. 2008 Dec;37(12):1156-8. Epub 2008 Sep 4. 14. Schaaf H, Lendeckel S, Howaldt HP, Streckbein P. Donor site morbidity after bone harvesting from the anterior iliac crest. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jan;109(1):52-8. 15. Abbah SA, Lam CX, Ramruttun AK, Goh JC, Wong HK. Fusion performance of low-dose recombinant human bone morphogenetic protein 2 and bone marrow-derived multipotent stromal cells in biodegradable scaffolds: a comparative study in a large animal model of anterior lumbar interbody fusion. Spine (Phila Pa 1976). 2011 Oct 1;36(21):1752-9. 16. Lee JH, Lee JH, Park JW, Lee HS. Fusion rates of a morselized local bone graft in polyetheretherketone cages in posterior lumbar interbody fusion by quantitative analysis using consecutive three-dimensional computed tomography scans. Spine J. 2011 Jul;11(7):647-53. Epub 2011 May 26. 17. Velchuru VR, Satish SG, Petri GJ, Sturzaker HG. Hernia through an iliac crest bone graft site: report of a case and review of the literature. Bull Hosp Jt Dis. 2006;63(3-4):166-8. Review. 18. Konishi S, Nakamura H, Seki M, Nagayama R, Yamano Y. Hydroxyapatite granule graft combined with recombinant human bone morphogenic protein-2 for solid lumbar fusion. J Spinal Disord Tech. 2002 Jun;15(3):237-44 19. Zermatten P, Wettstein M. Iliac wing fracture following graft harvesting from the anterior iliac crest: Literature review based on a case report. Orthop Traumatol Surg Res. 2012 Feb;98(1):114-7. Epub 2011 Nov 30. 20. Ishii S, Shishido F, Miyajima M, Sakuma K, Shigihara T, Tameta T, Miyazaki M, Hashimoto N. Imaging findings at the donor site after iliac crest bone harvesting. Skeletal Radiol. 2010 Oct;39(10):1017-23. Epub 2010 Feb 24. 21. Robertson PA, Wray AC. Natural history of posterior iliac crest bone graft donation for spinal surgery: a prospective analysis of morbidity. Spine (Phila Pa 1976). 2001 Jul 1;26(13):1473-6. 22. Porchet F, Jaques B. Unusual complications at iliac crest bone graft donor site: experience with two cases. Neurosurgery. 1996 Oct;39(4):856-9. 23. Sys J, Weyler J, Van Der Zijden T, Parizel P, Michielsen J. Platelet-rich plasma in mono-segmental posterior lumbar interbody fusion. Eur Spine J. 2011 Oct;20(10):1650-7. Epub 2011 Jul 10. 24. Glassman SD, Carreon L, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar JR. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J. 2007 Jan-Feb;7(1):44-9. Epub 2006 Nov 20. 25. Buttermann GR. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J. 2008 May-Jun;8(3):426-35. Epub 2007 Mar 7 26. Valdes MA, Thakur NA, Namdari S, Ciombor DM, Palumbo M. Recombinant bone morphogenic protein-2 in orthopaedic surgery: a review. Arch Orthop Trauma Surg. 2009 Dec;129(12):1651-7. Epub 2009 Mar 12. Review. 27. Rowan FE, O'Malley N, Poynton A. RhBMP-2 use in lumbar fusion surgery is associated with transient immediate post-operative leg pain. Eur Spine J. 2011 Dec 14. 28. Geibel PT, Boyd DL, Slabisak V. The use of recombinant human bone morphogenic protein in posterior interbody fusions of the lumbar spine: a clinical series. J Spinal Disord Tech. 2009 Jul;22(5):315-20. 29. Lin X, Elliot JJ, Carnes DL, Fox WC, Peña LA, Campion SL, Takahashi K, Atkinson BL, Zamora PO. Augmentation of osseous phenotypes in vivo with a synthetic peptide. J Orthop Res. 2007 Apr;25(4):531-9.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy